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Abstract
PRINCIPLES: In view of growing concern in recent years regarding medication errors as causes of
adverse drug events (ADEs), we explore the frequency and characteristics of error-associated ADEs in
medical inpatients. METHODS: All patients with ADEs or ADErelated hospital admission in a cohort
of medical inpatients identified by "event monitoring" (SAS/CHDM database, Br J Clin Pharmacol
2000:49:158-67) were evaluated independently by two experienced physicians. ADEs were first divided
into ADEs occurring during cohort stay (incident ADE) and ADE present prior to/at admission. ADEs
were then grouped as error-associated ADEs (eADEs: indication error, missed contraindication, wrong
dosage regimen or inadequate surveillance) and adverse drug reactions (ADRs: indication established,
no contraindications, appropriate dosage regimen and adequate surveillance). RESULTS: Among the
6383 patients analysed (100%), 481 (7.5%) experienced at least one incident ADE. Incident ADRs
occurred in 457 (7.2%). Incident eADEs were recorded in 28 patients, corresponding to an eADE
incidence of 0.4% (95% CI: 0.2, 0.7). Error types were missing/inappropriate indication (4 cases),
missed contraindications (9), relative overdoses (8), absolute overdoses (3) and inadequate clinical
surveillance (4). The responsible drugs included antithrombotics (6), cardiovascular drugs (5),
antibiotics (5), hypnotics (4) and non-steroidal anti-inflammatory drugs (3). ADE-related hospital
admissions were observed in 262 patients (4.1%); 183 (2.9%) were classified as ADRs and 79 (1.2%) as
eADEs. CONCLUSIONS: Incident eADEs were observed in 1 out of 250 patients and accounted for
approximately 6% of ADEs. In contrast, eADEs accounted for 30% of ADE-related hospital admissions.
Hence, in medical inpatients, eADEs represented a small fraction of total incident ADEs, whereas they
contributed significantly to hospital admissions.
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Principles: In view of growing concern in recent
years regarding medication errors as causes of 
adverse drug events (ADEs), we explore the fre-
quency and characteristics of error-associated
ADEs in medical inpatients. 
Methods: All patients with ADEs or ADE-
related hospital admission in a cohort of medi-
cal inpatients identified by “event monitoring”
(SAS/CHDM database, Br J Clin Pharmacol
2000:49:158–67) were evaluated independently 
by two experienced physicians. ADEs were first 
divided into ADEs occurring during cohort stay
(incident ADE) and ADE present prior to/at ad-
mission. ADEs were then grouped as error-associ-
ated ADEs (eADEs: indication error, missed con-
traindication, wrong dosage regimen or inade-
quate surveillance) and adverse drug reactions
(ADRs: indication established, no contraindica-
tions, appropriate dosage regimen and adequate
surveillance). 
Results: Among the 6383 patients analysed
(100%), 481 (7.5%) experienced at least one inci-
dent ADE. Incident ADRs occurred in 457 (7.2%).
Incident eADEs were recorded in 28 patients,
corresponding to an eADE incidence of 0.4%
(95% CI: 0.2, 0.7). Error types were missing/inap-
propriate indication (4 cases), missed contraindi-
cations (9), relative overdoses (8), absolute over-
doses (3) and inadequate clinical surveillance (4).
The responsible drugs included antithrombotics
(6), cardiovascular drugs (5), antibiotics (5), hyp-
notics (4) and non-steroidal anti-inflammatory
drugs (3). ADE-related hospital admissions were
observed in 262 patients (4.1%); 183 (2.9%) were
classified as ADRs and 79 (1.2%) as eADEs. 
Conclusions: Incident eADEs were observed 
in 1 out of 250 patients and accounted for approx-
imately 6% of ADEs. In contrast, eADEs ac-
counted for 30% of ADE-related hospital admis-
sions. Hence, in medical inpatients, eADEs repre-
sented a small fraction of total incident ADEs,
whereas they contributed significantly to hospital
admissions.
Key words: adverse drug events; preventable ad-
verse drug events; adverse drug reactions; medication
error; medical inpatients
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Adverse drug events (ADEs), usually defined
as harm caused by the (appropriate or inappropri-
ate) use of a drug [1], constitute a major health con-
cern for the individual patient and the community.
It has been estimated that ADEs account for ap-
proximately 5% of all hospital admissions, occur
during 10–20% of hospitalisations [2] and are re-
sponsible for 7–9% of hospitalisation days [3, 4].
ADEs can be classified according to their potential
preventability. They cannot be prevented if the
causative drug is used for an established indication,
in the absence of contraindications, at the appro-
priate dosage and under adequate surveillance.
These non-preventable ADEs are classified as 
adverse drug reactions (ADRs). All other ADEs 
are potentially preventable. These include ADEs
where the causative drug is used without an estab-
lished indication, despite the presence of con-
traindications, at an inappropriately high dosage,
as an inappropriate formulation, by an incorrect
route or under inadequate surveillance. These 
potentially preventable ADEs can be classified as
error-associated adverse drug events (eADEs). 
The currently available estimates of the inci-
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dence of eADEs in hospitalised patients vary con-
siderably. In 1991, Leape et al. evaluated the inci-
dence of several types of adverse event by review-
ing the records of more than 30 000 inpatients [5].
Among 178 ADEs, 17.7%, corresponding to ap-
proximately 32 ADEs, were caused by errors, re-
sulting in an eADE incidence of 0.11%. On the
basis of a review of 15 000 medical records from
Utah and Colorado, the incidence of eADEs was
estimated at 0.17% for patients aged between 16
and 64 years and at 0.64% for patients over 64 [6].
A prospective study in 1120 paediatric inpatients
resulted in a comparable eADE incidence of
0.45% [7]. In contrast, in three prospective stud-
ies Bates et al. estimated considerably higher
eADE incidences of 1.3%, 1.8% and 3.6% [8–10].
Furthermore, extrapolations of medication error-
associated death rates yielded an eADE-related
mortality estimate of up to 98 000 deaths per year
for the US [11], though these latter studies were
controversial  [12–14]. Since detailed knowledge
of the incidence and characteristics of eADEs are
a prerequisite for appropriate planning of error
prevention strategies and for adequate allocation
of financial resources, we evaluated the contribu-
tion of medication errors to total ADEs recorded
prospectively in the pharmaco-epidemiological
database SAS/CHDM (Stiftung für Arzneimittel-
sicherheit/Comprehensive Hospital Drug Moni-
toring) [4]. We determined the overall eADE inci-
dence and characterised eADEs with respect to
types of error, drugs involved and types of event.
We further estimated the contribution of eADEs
to hospital admissions. 
The SAS/CHDM (Stiftung für Arzneimittelsicher-
heit/Comprehensive Hospital Drug Monitoring) project
maintains a pharmaco-epidemiological database for study
of ADEs in a cohort of medical inpatients [4]. The cohorts
are located at the Departments of Medicine of Zürich
University Hospital and the Kantonsspital St. Gallen.
While the former is mainly a tertiary referral centre and
serves only as a primary hospital for some parts of the city,
the latter serves as a primary city hospital and as a second-
ary referral centre for northeast Switzerland. At Zürich
University Hospital the monitored units belong to the 
Department of Internal Medicine, where admissions are
based on available beds irrespective of the suspected diag-
noses, whereas in the Kantonsspital St. Gallen the moni-
tored units belong to one of three divisions of the Depart-
ment of Internal Medicine, preferentially focusing on in-
fectious, endocrine and pulmonary diseases. For each pa-
tient admitted to one of the monitored units we collect on
admission structured data regarding patient characteris-
tics, drug exposure before hospitalisation and the cause(s)
of hospital admission. During cohort stay, structured data
on “events” (symptoms, laboratory results) and drug ex-
posure are prospectively collected on a daily basis and en-
tered into the database. At discharge, data on diagnoses
(ICD10) are added. The monitoring physician also evalu-
ates the cause(s) of hospital admission and all clinical
events and pathological laboratory results with respect to
drug therapy and the patient’s disease(s). All possibly drug-
related events resulting in considerable discomfort, drug
withdrawal or dose reduction and/or initiation of thera-
peutic measures are classified and recorded as adverse drug
events (ADEs). Intentional (e.g. suicidal) drug overdoses
are excluded. Further details of the data recording proce-
dures in the SAS/CHDM project have been reported pre-
viously [4]. 
Among the hospitalisations monitored up to Decem-
ber 2000, we first extracted those who experienced at least
one adverse drug event(s) during cohort stay and/or ad-
verse drug events leading to hospital admission. For each
ADE extracted we determined whether the ADE was first
observed during cohort stay, i.e. represented an incident
ADE or was already present at hospital admission, i.e. rep-
resented an ADE at admission (figure 1). The latter were
further classified into ADEs leading to hospital admission,
i.e. ADE-related admissions, and other ADEs already pres-
ent at but unrelated to hospital admission, i.e. admissions
with ADE. 
Two experienced physicians independently re-evalu-
ated all ADEs  on the basis of database entries, physician’s
discharge letters and medical records, and determined
whether the ADE represented an ADR or an eADE (fig-
ure 1). ADEs were classified as adverse drug reaction (ADR)
if the causative drug was administered for an established
indication in the absence of contraindications, at the 
appropriate dosage and under adequate surveillance. Indi-
cations were considered appropriate if they were either 
included in the labelling or had been described elsewhere.
In contrast, ADEs were classified as error-associated
(eADE), if the causative drug was used inappropriately
with respect to selection, dosage or surveillance. Selection
errors included missing or inappropriate indications (indi-
cation errors), missed contraindications and missed drug
interactions. Dosage errors included a) absolute overdoses,
i.e. dosages exceeding the usual therapeutic, prophylactic
or diagnostic dosages, b) relative overdoses, i.e. dosages
too high for the individual patient, such as e.g. the stan-
dard therapeutic digoxin dosage in the case of impaired
renal function, and c) administration errors such as inap-
propriate formulation, wrong route of administration or
wrong dosage interval. Surveillance errors included eADEs
caused by inadequate clinical surveillance or insufficient
laboratory checks. For ADEs at admission, an additional
category called patient errors included eADEs caused by
the patients themselves. ADE severity was graded into a)
significant, i.e. ADEs demanding a dosage reduction or
therapy cessation, b) moderate, i.e. ADEs requiring addi-
tional therapeutic measures, c) serious, i.e. ADEs prolong-
ing hospitalisation, leading to permanent defects or life-
threatening complications, and d) lethal i.e. ADEs leading
to death. 
Methods
Figure 1
Venn diagram on 
adverse drug events
(ADE) and its sub-
division into incident
ADE vs. ADE at ad-
mission and error-
associated ADE
(eADE) vs. adverse
drug reaction (ADR).
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Interphysician rating differences were evaluated
using Cohen’s Kappa together with proportion of ob-
served agreement (po) and the observed proportions of
positive (ppos) and negative (pneg) agreement, where the ppos
and pneg indicate the consistency of the two observers on
positive and negative decisions [15, 16]. 
Incidence and prevalence rates were determined 
by dividing the number of patients with a corresponding
incident event or event at admission by the number of
monitored or exposed patients. The reported 95% confi-
dence interval corresponds to the exact 95% confidence
interval for proportions calculated by solving equations
(777) and (778) given in [17] for pe (the lower limit of the
95% confidence interval) and pr (the upper limit of the
95% confidence interval).The corresponding procedure
was programmed in Splus5.1, as the available tables with
exact 95% confidence intervals [17] are only applicable to
samples with a number of observations not exceeding 100.
Among 6383  patients (100%) monitored be-
tween 1996 and 2000, 62% were recorded in
Zürich and 38% in St. Gallen. 3710 (58%) were
males and 2673 (43%) females. The median (Q1,
Q3) age was 61 (45, 74) years. In 65%, 30%, 21%
and 23% of the hospitalisations at least one diag-
nosis concerned the cardiovascular system (ICD10
I00-I99), the respiratory system (ICD10 J00-J99),
infectious diseases (ICD10 A00-B99) and neo-
plasms (ICD10 D50-D89) respectively. The me-
dian (Q1, Q3) number of different drugs per patient
and day amounted to 6 (4, 8). The median (Q1, Q3)
cohort stay was 8 (5, 15) days. 344 patients (5.2%)
died during hospital stay. 
An incident ADE and/or ADE at admission
were recorded in 715 patients, corresponding to
11.2% of all patients monitored. At least one inci-
dent ADE was recorded in 481 patients (7.5%) and
an ADE at admission in 279 (4.4%). Thus, 45 pa-
tients who were admitted with ADEs also experi-
enced an incident ADE during hospitalisation.
Database entries, discharge letters and medical
records of these 715 patients were evaluated inde-
pendently by two experienced physicians. Cohen’s
Kappa and the related parameters for the classifi-
cation of ADEs as eADE or ADR amounted to 0.5
with po = 0.97, ppos = 0.5, pneg = 0.99 for the incident
ADEs and 0.9 with po = 0.96, ppos = 0.93, pneg = 0.97
for ADEs at admission.
Incident ADE
Among the 481 patients with at least one inci-
dent ADE, 457 experienced ADRs, resulting in an
ADR incidence of 7.2% (table 1). Overall, 28 inci-
dent eADEs were identified, corresponding to an
eADE incidence of 0.4%. Thus, 6% of all incident
ADEs or about 1 in 17 incident ADEs were due to
error. Four of the patients with incident eADEs
also experienced an incident ADR. In 12 (0.19%)
of the eADE cases, the eADE was classified as sig-
nificant, in 6 (0.09%) as moderate and in 10 (0.16%)
as serious (table 1). None of the incident eADE was
lethal. The causes of incident eADEs were selection
errors in 13 patients (0.20%), dosage errors in 11
(0.17%) and surveillance errors in 4 (0.06%) (figure
Results
patients
No. % (95% CI)
Total number of patients 6383 100
Patients with at least 481 7.5 (6.8, 8.2)
1 incident ADE
Patients with ADR * 457 7.2 (6.5, 7.8)
Patients with eADE * 28 0.4 (0.2, 0.7)
significant 12 0.19 (0.08, 0.30)
moderate 6 0.09 (0.01, 0.17)
serious 10 0.16 (0.03, 0.26)
lethal 0 0 (0, 0.05)
* In 4 patients, an ADR as well as an eADE was observed.
Figure 2
Incident error-associ-
ated adverse drug
events (eADE) in
medical inpatients
according to type of
error (A), systems or
organs (B) and drug
class (C). Significant:
ADEs demanding a
dosage reduction or
therapy cessation,
moderate: ADEs re-
quiring additional
therapeutic measures
and serious: ADEs
prolonging hospitali-
sation or leading to a
permanent defect or
life-threatening com-
plication. Types of
error include selec-
tion errors i.e. indica-
tion errors, missed
contraindications and
missed drug interac-
tions, dosage errors
i.e. absolute over-
doses, relative over-
doses, dosing fre-
quency and route er-
rors and surveillance
errors i.e. inadequate
clinical surveillance
or neglected labora-
tory determinations.
The drug classes are
antithrombotics
(ATC: B01), cardio-
vascular drugs (C),
antibacterials for sys-
temic use (J01),
sedatives (N05B and
N05C), NSAIDs i.e.
non-steroidal anti-
inflammatory drugs
(M01A), antidiabetics
(A10) and opioids
(N02A). 
Table 1
Incidence of adverse drug reactions (ADRs) and error-associ-
ated adverse drug events (eADEs) in medical inpatients.
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2A). The systems and organs most frequently af-
fected by eADEs were the gastrointestinal tract,
the haemostasis system, the skin and the respira-
tory and cardiovascular systems (figure 2B). The
drug classes most frequently causing eADEs were
antithrombotics (ATC B01), cardiovascular drugs
(C*), antibacterials (J01), sedatives (N05B/C) and
non-steroidal anti-inflammatory drugs (NSAIDs,
M01A) (figure 2C). If we compare the number of
eADEs with the number of patients exposed to the
corresponding drug classes, eADE incidences
were 0.42% for NSAIDs, 0.20% for antibacterials,
0.15% for antithrombotics, 0.12% for cardiovas-
cular drugs and 0.11% for sedatives. Thus, eADEs
were observed with an overall incidence of 0.4%,
related chiefly to selection and dosage errors and in-
volving several organ systems and drug classes. 
Table 2 reports additional details on the
eADEs in the 28 incident cases. Among the selec-
tion errors, 4 cases represented indication errors
and 9 missed contraindications. In 2 of the 4 cases
with indication errors, the patients had no clear 
indication for anticoagulation but experienced
bleeding complications. Among the cases caused
by missed contraindications, 4 patients experi-
enced allergic skin reactions against antibacterials
despite known allergy against the same drugs.
Three further patients suffered from bleeding
complications in the presence of known con-
traindications against NSAIDs and/or anticoagu-
lants. Among the dosage errors, the causes were
mainly overdoses of benzodiazepines (4 cases) and
digoxin (4 cases). The 3 absolute overdose cases in-
cluded 2 cases of benzodiazepine overdose occur-
ring during intravenous sedation with midazolam
for a medical intervention and after repeated gen-
erous lorazepam administrations in an opioid-ad-
dicted patient. The third patient with an absolute
overdose developed somnolence while receiving
high doses of combined clozapine and morphine.
Two further patients exhibiting benzodiazepine
oversedation suffered from polymorbidity with
Table 2
Medical inpatients
with an eADE. 
Patient drug events, contraindications and risk factors severity
Selection errors: Indication errors
F 89 phenprocoumon skin and muscle haematomas moderate
M 72 phenprocoumon muscle haematoma significant
F 60 iloprost hypotension, abdominal cramping significant
F 70 nasal decongestant rhinitis medicamentosa significant
Indication errors: Missed contraindications
M 68 amoxicillin, clavulanic acid rash and skin oedema, known amoxicillin allergy serious
M 46 amoxicillin, clavulanic acid rash, known amoxicillin allergy significant
M 62 amoxicillin, clavulanic acid rash, known amoxicillin allergy significant
M 58 co-trimoxazole rash, known co-trimoxazole allergy significant
M 40 diclofenac, acetylsalicylic acid GI bleeding, history of peptic ulcer disease moderate
F 80 acetylsalicylic acid GI bleeding, history of peptic ulcer disease serious
M 75 phenprocoumon subdural haematoma, multiple risk factors for falls serious
F 63 ceftriaxone thrombopenia, previous ceftriaxone-associated thrombopenia serious
M 69 flurbiprofen aggravation of known renal insufficiency significant
Dosage errors: Absolute overdoses
M 36 midazolam respiratory insufficiency serious
M 19 lorazepam somnolence moderate
M 93 morphine, clozapine somnolence significant
Relative overdoses
F 78 digoxin nausea and vomiting, renal insufficiency moderate
F 96 digoxin vomiting, renal insufficiency moderate
M 79 digoxin nausea, renal insufficiency significant
F 84 digoxin blurred vision, renal insufficiency significant
M 43 midazolam respiratory insufficiency, hepatic insufficiency moderate
M 69 lorazepam nocturnal apnea episodes , multimorbidity moderate
F 75 metoprolol bradycardia and hypotension, rapid dose escalation serious
M 92 paracetamol toxic liver injury, old age and poor nutrition significant
Surveillance errors
F 45 phenprocoumon, heparin large psoas haematoma leading to N. femoralis impairment serious
M 60 heparin haematoma requiring surgical treatment and transfusions serious
F 84 intravenous insulin hypoglycaemia, inadequate control of blood glucose levels serious
M 77 iron phlebitis after paravenous infusion significant
For each of the 28 incident cases, patient data (sex, age), the causative drug(s), the eADE predisposing risk factors (for relative 
overdosages) and the severity are included. The cases are classified according to the types of error.
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impaired renal function and hepatic insufficiency
respectively, and were therefore classified as rela-
tive overdoses. All four patients with digoxin tox-
icity exhibited impaired renal function and thus
also represented relative overdose cases. Since,
overall, 594 patients were treated with digoxin, the
eADE incidence for digoxin was 0.64%. Among
ADEs caused by surveillance errors, two further pa-
tients exhibited bleeding complications. On the
basis of the 4 phenprocoumon-associated eADEs
and the 946 phenprocoumon-treated patients, the
eADE incidence for phenprocoumon was 0.42%.
In summary, the eADEs consisted mainly of aller-
gic reactions to antibacterials in patients with
known allergy, bleeding complications associated
with inappropriate indications, missed contraindi-
cations and/or inadequate surveillance and over-
doses of benzodiazepines and digoxin. 
ADE at admission
Overall, 279 (4.4%) patients presented with an
ADE at admission (table 3). 194 (3.0%) of these ex-
hibited ADRs and 85 (1.3%) eADEs. Among the
194 patients with ADR at admission, 183 (2.9%)
were admitted for the ADR and therefore classi-
fied as ADR-related admissions. The remaining 11
(0.2%) presented with an ADR at admission but
were admitted for other conditions and thus rep-
resent admissions with ADR. In 79 (1.2%) of the
85 patients with eADE at admission, the eADE was
the cause of the admission and these cases there-
fore represent eADE-related admissions. In 6 pa-
tients (0.1%) the eADE was detected at admission
but the patients were admitted for other condi-
tions, i.e. they represented admissions with eADE.
Errors were thus causative in about 1 in 3 cases for
both subgroups of ADE at admission, i.e. for ADE-
related admissions and admissions with ADE. The
causes of eADEs at admission were selection errors
in 36 cases (0.56%), dosage errors in 10 (0.16%) and
surveillance errors in 15 (0.23%) (figure 3A). Among
the selection errors, 14 were indication errors, 9
missed contraindications and 13 missed drug in-
teractions. The dosage errors occurred due to rela-
tive overdoses in 4 cases and to absolute overdoses
in 3. In the remaining 3 cases, the errors concerned
the route of administration and the dosage inter-
val. Interestingly, in 24 (0.4%) of the 85 cases with
eADE at admission the error was induced by the
patient and not by a health professional, and these
cases thus represent patient errors. The eADEs at
admission most frequently concerned the gas-
trointestinal tract, the kidney and the cardiovascu-
lar or central nervous systems (figure 3B), and were
commonly caused by NSAIDs, cardiovascular
drugs and antithrombotics (figure 3C). Frequently
observed eADEs at admission were NSAID-asso-
ciated gastrointestinal complications (25 cases): of
these, 8 cases took the NSAID without contacting
a health professional (patient errors), 5 were caused
by a combination of NSAIDs with anticoagulants
(missed drug interactions), 2 received an NSAID
despite a known history of peptic ulcer (missed
contraindications) and 2 were treated with a com-
bination of two or more NSAIDs (indication er-
rors). Five patients were admitted for NSAID-
associated renal insufficiency (2 patient errors, 2 in-
dication errors and 1 missed contraindication). 13
patients were admitted for cardiovascular agent-
induced hypotension or bradycardia (3 missed
drug interactions, 6 surveillance errors, 2 patient er-
rors, 1 indication error and 1 relative overdose).
The severity of the eADEs at admission was signifi-
Figure 3
Error-associated drug
events (eADE) at ad-
mission according to
type of error (A), sys-
tems or organs (B)
and drug class (C).
Significant: ADE 
demanding a dosage
reduction or therapy
cessation, moderate:
ADEs requiring addi-
tional therapeutic
measures, serious:
ADEs prolonging hos-
pitalisation or leading
to a permanent defect
or life-threatening
complication and
lethal: ADEs leading
to the patient’s death.
Types of error include
selection errors i.e.
indication errors,
missed contraindica-
tions and missed
drug interactions,
dosage errors i.e. 
absolute overdoses,
relative overdoses,
dosing frequency and
route errors, surveil-
lance errors i.e. inad-
equate clinical sur-
veillance or neglected
laboratory determina-
tions and patient er-
rors. The drug classes
are antithrombotics
(ATC: B01), cardio-
vascular drugs (C),
antibacterials for 
systemic use (J01),
sedatives (N05B and
N05C), NSAIDs i.e.
non-steroidal anti-
inflammatory drugs
(M01A), antidiabetics
(A10), opioids (N02A)
and immunosuppres-
sive agents (L04).
patients
No. % (95% CI)
Total number of patients 6383 100
ADE at admission 279 4.4 (3.8, 4.9)
ADR at admission 194 3.0 (2.6, 3.5)
ADR-related admission 183 2.9 (2.4, 3.3)
Admission with ADR 11 0.2 (0.07, 0.3)
eADE at admission 85 1.3 (1.0, 1.7)
eADE-related admission 79 1.2 (0.9, 1.5)
Admission with eADE 6 0.1 (0.01, 0.2)
Table 3
Frequency of adverse drug reactions (ADRs) and error-asso-
ciated adverse drug events (eADEs) at hospital admission.
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cant in 2 cases (0.03%), moderate in 4 (0.06%), se-
rious in 77 (1.2%) and lethal in 2 (0.03%) (figure 3).
Bleeding complications from oral anticoagulation
without comprehensible indication caused one of
the 2 eADE-related fatalities. The other fatality
concerned a patient who had consulted at least two
physicians for angiooedema and finally died of 
hypoxic brain damage due to enalapril-induced 
angiooedema. In summary, 1.2% of all admissions
were caused by eADEs, with two-thirds caused by
health professionals and one-third by the patients
themselves. 
In this study we determined the incidence of
eADE in a cohort of 6383 medical inpatients hos-
pitalised in two Swiss teaching hospitals as 0.4%.
Six per cent of all incident ADE, or about 1 in 17
incident ADE, were caused by error (table 1). The
most frequently observed types of error in patients
with incident eADE were missed contraindica-
tions and relative dosage errors (figure 2, Table 2).
Further, eADEs at admission were observed in
1.3% of all patients and contributed about 1 in 3
of ADEs at admission (table 3). In the majority of
patients with eADEs at admission, the eADE was
the cause of hospital admission (table 3). eADEs at
admission were eventually lethal in 0.03% of pa-
tients. Among the eADEs at admission, the most
frequent error types were missed drug interac-
tions, surveillance and patient errors (figure 3). 
The eADE incidence rate of 0.4% obtained in
the present study agrees well with the values ob-
tained in several other studies [5–7, 18]. Further-
more, the overall incident ADE rate of 7.5% in 
this study is close to the value of 6.5% reported 
by Bates et al. [9, 19, 20], although Bates et al. 
reported considerably higher eADE rates of
1.3%–3.6% [8–10, 19, 20]. Differences between
centres are a well-known phenomenon in epidemi-
ological studies and may be due to local differences
in drug utilisation, patient populations and/or
methodological differences [21]. In our study, for
example, the incident eADE list is headed by
digoxin, NSAIDs, antithrombotics, cardiovascu-
lars, antibacterials and sedatives, whereas Bates’s
list is headed by analgesics, antibacterials, sedatives
and antipsychotics [9]. This suggests that anal-
gesics and antipsychotics may have been adminis-
tered less frequently in our patient cohort, result-
ing in lower eADE rates for these drugs and thus
lower overall eADE rates. Another possible cause
of eADE incidence differences are differences in
patient collectives; our study cohort was limited to
general medical care units and did not include in-
tensive care units, which show an approx. twofold
higher eADE rate [9]. eADE incidence differences
may also have resulted from methodological dif-
ferences in ADE screening. ADEs in our study
were recorded prospectively; the study physicians
visited the monitored units daily on workdays, a
procedure which has so far resulted in rather high
eADE incidence rates [9, 19, 20]. Further, individ-
ual differences in the perception of preventability,
as discussed recently for error-associated deaths
[22], may influence eADE incidence estimates.
The internal validity of our results is supported by
Cohen’s Kappa statistics with moderate to excel-
lent agreement between the two experienced
physician evaluators for the classification of ADEs
as eADE or ADR. 11 of the 28 incident eADE cases
were identified independently by both evaluators
and 8 and 9 incident eADE cases were identified
by one of them, suggesting that a maximum of 
7 incident eADE cases may have been missed by
both reviewers. The reported interstudy incidence
differences show how important it is to clearly de-
fine eADEs, to validate local methodology, to have
all ADE cases assessed by independent reviewers,
to know the local eADE incidence rates and to
evaluate directly changes in local eADE incidence
rates in future error intervention studies.
The errors leading to incident eADEs chiefly
involved missed contraindications and relative
overdose errors. This is in line with another study
on medication errors in inpatients, which also
showed a predominance of incorrect drug choices
and drug dosage errors [19]. If we extrapolate from
the values of 1 in 100 errors leading to an eADE
[1, 8], errors should have occurred in about 4% of
all patients included in the database. In view of the
high error rates reported, electronic prescribing
may be a promising way of reducing error rates in
the future. For eADE reduction, sophisticated
software solutions will be required to ensure that
dosages are adjusted according to the individual
patient’s needs. For example, dosage adjustment
for digoxin in renal insufficiency can only be tack-
led by cross-linking with the patient’s age, the pa-
tients’ plasma creatinine laboratory data and the
nurse’s recordings on the patients’ body weight
[23]. Relative overdoses of psychotropics and
missed contraindications will be even more diffi-
cult to prevent, since this requires cross-linking
with structured patients’ history and diagnostic
data. However, prospective eADE prevention re-
mains the only approach in proving that ADEs
classified retrospectively as error-associated are in-
deed preventable. 
Considering the low overall incident eADE
rate, it was surprising that 1.2% of all patients were
admitted because of eADEs (table 3). Since we lack
exposure data, we cannot quantify the associated
risk. However, if we consider that annually about
10% of the Swiss population are admitted to hos-
pital, a rough estimate would be that each year up
to 0.1% of the population are hospitalised because
of eADEs. For eADEs at admission, electronic
Discussion
Adverse drug events caused by medication errors in medical inpatients 670
prescription and the overview of all medications by
a primary care physician or pharmacist would be
sufficient to detect and possibly prevent missed
drug interactions. However, tackling patients’ er-
rors and surveillance errors will be considerably
more difficult.
In this analysis two eADEs with lethal out-
come were detected. In addition, we observed five
deaths due to incident ADRs and three deaths due
to ADRs at admission [4] (data not shown). Thus,
ten ADE-related deaths were observed overall,
corresponding to 3% of all deaths and 0.16% of all
patients. The former number is close to the value
of 5% ADE-related deaths in a recent study eval-
uating 1511 in-hospital deaths [24] and somewhat
lower than the 9% directly drug-related deaths in
another study also evaluating 732 in-hospital
deaths [25]. Most of ADR-related deaths (6 of 8
deaths) were cancer chemotherapy-related [4]. It
is reassuring that overall we observed only two
eADE-related deaths, both of which occurred in
patients admitted for the corresponding eADEs,
resulting in an overall rate of eADE-related deaths
of 0.03%. Again, the number of 0.03% seems more
worrisome, if we consider that 0.03% of the 10%
of the population admitted to hospital per year
could die of eADEs, corresponding to some 3
eADE-related deaths per 100 000 population per
year. Such extrapolations to the entire country
must of course remain speculative, since there may
be considerable local differences in drug utilisa-
tion, prescription and surveillance. However, the
patient who died because of enalapril-associated
angiooedema despite multiple physician contacts
for this complaint demonstrates the importance of
adequate therapy surveillance and prompt recog-
nition of possible ADEs.
In conclusion, we determined an overall eADE
incidence of 0.4% in a cohort of 6383 medical in-
patients and identified missed contraindications
and relative dosage errors as the main causes of
eADEs in inpatients. eADEs were associated with
a variety of drugs and symptoms. Furthermore,
with an incidence of 1.2% eADE contribute con-
siderably to hospital admissions. In contrast to in-
hospital eADEs, eADEs at admission were chiefly
caused by patients’ errors, missed drug interac-
tions and surveillance errors. Further investigation
will be needed to determine whether sophisticated
electronic prescribing and elaborate decision sup-
port systems will substantially reduce eADE rates.
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